Immutep Insider Holds Steady: Owner’s 4M Shares Stay Put Amidst Volatile Valuation and 2026 Trial Stakes
Insider activity shows Immutep’s CEO holds steady stake while receiving performance‑right grants tied to upcoming trials, indicating long‑term upside despite low price.
2 minutes to read